Hi Ladies An update! I stopped X after my fourth round as my body simply cannot tolerate chemo. I now have constant, low grade shaking and tinnitus. And of course exhaustion. The neuropathy has stuck around, but honestly that is the least of my worries. Has anyone else experienced shaking? My doc refuses to test for pareneoplastic syndrome, which is what I think it is. Big hugs from Denmark Elisa
EA1131 Trial: Platinum Not Equal to Capecitabine for Residual Disease in Triple-Negative Breast Cancer
In patients withtriple-negative breast cancer who have residual disease after neoadjuvant chemotherapy, adjuvant capecitabine remains the standard of care. In the multicenter randomized noninferiority EA1131 trial, which included primarily basal tumors, noninferiority of adjuvant platinum over capecitabine could not be demonstrated, according toIngrid A. Mayer, MD, MSCI, of Vanderbilt University, Nashville, who presented the findings at the 2021 ASCO Annual Meeting.1
“The available data show that platinum agents are unlikely to be noninferior or superior to capecitabine in improving invasive disease–free survival, regardless of intrinsic subtype,” Dr. Mayer said. “The study definitely reinforces the role of capecitabine in this high-risk group.”
Of note, the 3-year invasive disease–free survival rate was lower than expected, regardless of study treatment: 42% in the platinum arm and 49% in the capecitabine arm. In the CREATE-X trial, which established the value of adjuvant capecitabine for residual disease, the 5-year disease-free survival was 70% with capecitabine and 56% with observation.2
KEY POINTS
The randomized noninferiority EA1131 trial aimed to determine whether adjuvant treatment with a platinum may be better than capecitabine in patients with early triple-negative breast cancer and residual disease after neoadjuvant therapy.
Preclinical models have suggested these tumors may be sensitive to platinum.
The study could not demonstrate noninferiority or superiority of the platinum.
The 3-year invasive disease–free survival rates were low with either treatment: 42% with platinum and 49% with capecitabine.
Capecitabine remains the adjuvant treatment of choice in this population.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot delete your posts in this forum You cannot edit your posts in this forum You cannot create polls in this forum You cannot vote in polls in this forum